Clinical Phase Equipment & Supplies In Mexico
224 equipment items found
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:BCN Peptides S.A. based inSant Quintí de Mediona, SPAIN
Where can BCN Peptides assist your peptide project? BCN Peptides is an industrial manufacturer with the capacity to produce from milligram to multi-kg batches of pharmaceutical peptides. We are experts in the synthesis of long and complex New Chemical Entities. BCN Peptides ensures the highest qualities and shortest times thanks to our experience in the manufacturing of peptides for all clinical ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA is advancing a robust pipeline of both proprietary and partnered therapeutic ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior has the right to select GABAB PAM drug candidates from our research ...
Manufactured by:Poietis based inPessac, FRANCE
NGB-C is a clinical-grade, GMP-compliant Bioprinter designed to meet the needs of Advanced Therapy Medicinal Products (ATMP) production and the requirements of Poietis’ ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
by:Genmab A/S based inCopenhagen V, DENMARK
DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent ...
by:Palvella Therapeutics. based inWayne, PENNSYLVANIA (USA)
QTORIN™ rapamycin 3.9% is a novel targeted topical therapy being studied for Microcystic Lymphatic Malformations (Micro LM). Palvella is enrolling a phase 2 clinical study for people with Micro ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
We are developing muscarinic acetylcholine receptor subtype 4 positive allosteric modulator, or M4 PAM, as a novel orally available treatment for schizophrenia & other psychosis. Schizophrenia affects approximately 24 million people worldwide, requiring lifelong treatment to reduce severe impact on their everyday life. The market for antipsychotics represents over $7B annual sales in the ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX14, recombinant anti-RANKL human monoclonal antibody injection, a denosumab biosimilar. It is potentially indicated for the treatment of postmenopausal women with OP at high risk for fracture. First subject has been doesd in the international multi-centre phase 3 clinical trial in China for the treatment of postmenopausal osteoporosis in women with high fracture ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
BridgeBio is working to create a potential first-ever systemic treatment for dystrophic epidermolysis bullosa (DEB), a disease caused by loss of function of Collagen 7 (C7) protein. PTR-01 is a C7 protein replacement therapy designed to restore the missing collagen protein (C7) at the root of the disease. Mutations in the gene that encodes C7 enable the epidermis to separate from the dermis. Even ...
by:Horizon Therapeutics plc based inSaint Kevin`s, IRELAND
A fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. We are investigating daxdilimab in dermatomyositis, discoid lupus erythematosus and lupus nephritis as well conducting Phase 2 clinical trials in alopecia areata and systemic lupus ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven cancers. Multiple Phase 3 clinical trials are currently enrolling; please explore www.clinicaltrials.gov for more information. TRUSELTIQ™ (infigratinib) obtained accelerated approval by FDA, was conditionally approved by Health Canada and received ...
Manufactured by:ViruSure GmbH based inVienna, AUSTRIA
Recombinant proteins are proteins expressed in cell lines which have been genetically modified by DNA recombinant technology. These therapeutics include recombinant blood clotting factors, hormones, enzymes, interferons, growth factors and other bioengineered ...
Manufactured by:BridgeBio Pharma, Inc. based inPalo Alto, CALIFORNIA (USA)
Infigratinib (BGJ398), is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of FGFR-driven conditions, including achondroplasia, a bone growth disorder in children. Overactivating FGFR3 mutations drive downstream MAPK and STAT1 signaling that aberrates growth plate development, thereby causing disproportionate short stature and serious ...
Manufactured by:Triple Hair Inc. based inDieppe, NEW BRUNSWICK (CANADA)
This innovative triple combination therapy promotes hair regrowth in men with androgenic alopecia. Its exclusive combination of molecules acts at various stages of the hair growth cycle to stop hair loss and stimulate regrowth, while also making hair thicker and darker. The effectiveness of this revolutionary solution was proven in the first two phases of clinical trials, where participants all ...
Manufactured by:iMouse GmbH based inBerlin, GERMANY
The iMouse DigiFrame offers a sophisticated solution for researchers looking to digitize rodent home-cage monitoring systems without disrupting existing setups. It is designed to retrofit onto current rack systems, providing continuous 24/7 observation capabilities. This system incorporates high-resolution infrared cameras with a dual-spectrum light system to ensure artifact-free imaging during ...
Manufactured by:Vedanta Biosciences, Inc based inCambridge, MASSACHUSETTS (USA)
VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection. VE303 consists of 8 types of clonal human commensal bacteria strains selected for their ability to provide colonization resistance to C. difficile and manufactured under cGMP conditions. It is produced under cGMP conditions from pure, clonal ...
by:Zymeworks Inc based inVancouver, BRITISH COLUMBIA (CANADA)
ZW49 is a HER2-targeted antibody drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ platforms. ZW49 is currently being evaluated in a Phase 1 clinical trial as a treatment for patients with locally advanced or metastatic HER2-expressing cancers that have progressed following treatment with existing approved therapies, including HER2-targeted ...
Manufactured by:Shanghai Henlius Biotech, Inc based inShanghai, CHINA
HLX04-O, recombinant anti-VEGF humanised monoclonal antibody injection. It is indicated for wet age-related macular degeneration (wAMD). HLX04-O was granted Phase 3 clinical study approvals in Australia, the United States, Singapore and the EU countries such as Latvia, Hungary and Spanish. In April 2022, the first patient in Australia and Latvia was dosed in the global multicentre phase 3 ...